197654-69-6

Upstream product

• 187679-57-8 tert-butyl (2S,3S)-3-({[2-(methyloxy)phenyl]methyl}amino)-2-phenylpiperidinecarboxylate 
• 136982-36-0 (2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine 
• 187679-58-9 (2S,3S)-3-Amino-1-tert-butoxycarbonyl-2-phenylpiperidine 

Downstream Products

• 197654-28-7 (2S,3S)-3-(5-(1-cyanoethyl)-2-methoxybenzyl)amino-2-phenylpiperidine 

Relevant academic research and scientific papers

3-[5-substituted benzyl)amino]-2-phenylpiperidines as substance P antagonists

This invention provides a compound of the formula: STR1 and its pharmaceutically acceptable salts, wherein R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl or terahydropyranyl, having one or more substituents selected from cyano, 1,3-thiazolanyl, COOR 2, COR 2, OCOR 2, CONR 3 R 4, NR 3 R 4, NR 5 COR 3 and C.ident.CR 6, wherein R 2 is hydrogen or C 1 -C 4 alkyl, R 3 and R 4 are independently hydrogen, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl, R 5 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl and R 6 is hydrogen, halo, cyano, C 1 -C 6 alkyl, COOH, COO(C 1 -C 4 alkyl) or phenyl; X is C 1 -C 6 alkoxy or halo C 1 -C 6 alkoxy; and Ar is phenyl optionally substituted with halo.These compounds are useful in the treatment of allergic disorders, angiogenesis, gastrointestinal disorders, central nervous system disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine, sunburn, and diseases, disorders and adverse conditions caused by Helicobacter pylori, in a mammalian subject.